Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, tolerability, and pharmacokinetics study of AST-004 intravenous infusion in healthy adults
NL-OMON53360Phase 1Active, not recruiting
- Sponsor
- Astrocyte Pharmaceuticals Inc.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind trial of AST-004 in ischemic stroke, traumatic brain injury (TBI), concussion (mTBI) and 1 more (2 arms), sponsored by Astrocyte Pharmaceuticals Inc. Primary endpoint: Safety and tolerability of AST-004. Started Apr 2023; status: active, not recruiting.
02
Drugs
AST-004
03
Conditions
ischemic stroketraumatic brain injury (TBI)concussion (mTBI)Neurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on NL-OMON53360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53360.